NCT03399786 - Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 18, 2018

Primary Completion Date

June 10, 2019

Study Completion Date

March 17, 2020

Conditions

Homozygous Familial Hypercholesterolemia

Interventions

DRUG

evinacumab

IV administration of evinacumab

DRUG

Placebo

IV administration of placebo

Trial Locations (30)

2000

Regeneron Research Site, Parktown

2050

Regeneron Research Site, Camperdown

6000

Regeneron Research Site, Perth

6020

Regeneron Research Site, Innsbruck

10029

Regeneron Research Site, New York

13385

Regeneron Research Site, Marseille

17674

Regeneron Research Site, Athens

33434

Regeneron Research Site, Boca Raton

45227

Regeneron Research Site, Cincinnati

45500

Regeneron Research Site, Ioannina

61039

Regeneron Research Site, Kharkiv

61176

Regeneron Research Site #2, Kharkiv

75651

Regeneron Research Site, Paris

76075

Regeneron Research Site, Ivano-Frankivsk

78226

Regeneron Research Site, Dallas

80131

Regeneron Research Site # 2, Napoli

97239

Regeneron Research Site, Portland

02114

Regeneron Research Site, Boston

G7H 7K9

Regeneron Research Site, Chicoutimi

G1V 4W2

Regeneron Research Site, Québec

830-8522

Regeneron Research Site, Kurume

662-0918

Regeneron Research Site, Nishinomiya

920-8641

Regeneron Research Site, Kanazawa

565-0871

Regeneron Research Site #3, Suita

565-8565

Regeneron Research Site, Suita

530-0001

Regeneron Research Site, Osaka

1105 AZ

Regeneron Research Site, Amsterdam

3045 PM

Regeneron Research Site, Rotterdam

02660

Regeneron Research Site #2, Kyiv

03680

Regeneron Research Site, Kyiv

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY